Is Kyntra Bio going out of business?

KYNTRA BIO, INC. (KYNB) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

KYNTRA BIO, INC. (KYNB) scores 23 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: FCF margin: -792.22%

Five questions, kept separate

Survival - Resilient

25-35 mo of estimated runway from 2026-06-30, based on $91.3M of cash and short-term investments against $36.6M of annual burn.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

281.2% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• FCF margin: -792.22%
• Interest coverage: -5.4x
• Revenue CAGR (3Y): -64.23%
• Revenue growth YoY: -209.35% (YoY)
• Cash Burn Deceleration: 1584.40% QoQ improvement (Rapid improvement)
• Cash Runway (years): 2.50y
• Price / Sales: 7.0x (see Valuation)
• Price / Earnings: 0.2x (see Valuation)
• Shares dilution YoY: 0.20% (YoY)
• Return on Assets: 181.24% (profit not operating-backed)

Read from filings through 2026-08-13.

Price as of 2026-09-07.